AI drug discovery risks FDA bottleneck
The guest argued that while AI can dramatically speed up drug discovery, the existing FDA clinical trial and approval process risks becoming a major bottleneck, negating the front-end gains.
Keep reading this one
You've read the thesis and who argued it. A free account opens the argument, what validates it, the risks the show raised, and the moment in the episode where it was said — 3 ideas in full a day, no card.